Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. - Wikidata - awgldk - TriplyDB

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

http://www.wikidata.org/entity/Q32085397

about

Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities Macrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid.A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages.Fluorescent high-content imaging allows the discrimination and quantitation of E-LDL-induced lipid droplets and Ox-LDL-generated phospholipidosis in human macrophages.Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand Control of macrophage activation and function by PPARs.15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice.Animal models of ischemic stroke. Part one: modeling risk factors.Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.PPAR Gamma Expression Levels during Development of Heart Failure in Patients with Coronary Artery Disease after Coronary Artery Bypass-Grafting.Peroxisome proliferator-activated receptors.Peroxisome proliferator-activated receptor gamma and atherosclerosis.PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.Orphan nuclear receptors find a home in the arterial wall.Animal models of cardiovascular diseases Vascular effects of GI262570X (PPAR-gamma agonist) in the brown adipose tissue of Han Wistar rats: a review of 1-month, 13-week, 27-week and 2-year oral toxicity studies.Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.Stabilization of atherosclerotic plaques: new mechanisms and clinical targets.PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages Peroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis.mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance.The Role of PPARgamma in pulmonary vascular disease The role of peroxisome proliferator-activated receptors in pulmonary vascular disease.Peroxisome proliferator-activated receptor ligands in atherosclerosis.Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis.Peroxisome proliferator-activated receptor gamma: the more the merrier?Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice.The inflammation highway: metabolism accelerates inflammatory traffic in obesity.Roles for lipid-activated transcription factors in atherosclerosis.Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.Combinatorial roles of nuclear receptors in inflammation and immunity.The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases.

P2860

Q28512042-C3364DA0-794F-46FD-84DA-3931DD41388E Q28513582-91F29E23-2245-4352-ACA3-366840CB2B10 Q30551530-8E4144AC-9DBB-4A21-8B2C-B0DA1FEFBE8F Q33514871-BC6F9BF4-37D9-4CE0-A771-2243E784BA23 Q33518799-DE16AE22-E714-4E34-840E-DDAF6C7628B7 Q33585657-39DC50DD-11E8-4D4A-8612-DD4D4AAD96ED Q33639520-A30D2C1A-DE89-41FA-8CED-C90BAAD9A25F Q33849597-DF069819-A6CC-485A-83EE-E3A8EF8EEA2E Q33962601-F1CB00CC-D24B-4E17-BF4A-25FCAC2393FB Q34049297-C8DC7C42-8B30-4DE9-B901-0E453D11CF75 Q34086707-7CE88304-5164-415D-B312-0E73F6B8ED56 Q34165847-F9E4F911-4F7E-46B7-8397-E525DBF1A73E Q34299000-0E1DEC3F-7C42-426C-873F-4F9C4AD872A8 Q34412608-ACE2B208-14BD-4412-907F-CF910A1702CC Q34482158-CE4B630B-5BA1-404E-BE23-FE022345A88D Q34492831-BC94ACEF-E8C9-48BD-813E-861F3BC34F5E Q34509964-C7768614-AA73-47DD-AEB7-2555B71578B6 Q34586834-F1A0921F-8EB8-4B28-81B4-316DAF461E1F Q34591282-2D114A74-E435-4B29-94F6-7CAB449571C5 Q34790065-17DE2ADF-C4D4-40D3-B4BB-6C19E6CCADB4 Q34895911-CF277689-8630-46BE-B57E-4C0A1BFA2D2E Q34962291-2683EDCB-E1DD-4F8D-B541-5BE0D15E90FB Q34986368-485A9D54-07AC-4148-9645-B346FD07A6A5 Q35144057-604A0373-B672-4B0B-AE24-3A8BB3F5E001 Q35309535-99F5C510-A235-4AE7-B5D2-833460521665 Q35588934-8D048C29-8FBB-48CE-AAA8-8F6A559EB3A8 Q35636695-97B25E6F-E820-4ECD-8247-51DBC65A1266 Q35794254-4A14FB8B-68FE-4A61-B889-E17B45404E84 Q35925357-C25B66C5-C063-4A03-9C39-9B0A1E513842 Q35925566-354780A4-1E03-4939-840A-C383CA71A98C Q36007212-E2FB39E8-962B-483C-90B4-9F8F62680E04 Q36012843-F8534AC1-8231-4C3E-BF34-01D3ECCF0A92 Q36018557-388B842B-2FF1-47A4-8F94-E82F312E8266 Q36076407-C9BC6484-1054-4857-B340-B81F92B97F82 Q36174974-5A65D60D-3941-40CD-9D89-B8F8224493AE Q36278716-7458B9B6-1584-4F50-A9D8-89E093B49D98 Q36401585-C71AA198-8156-4556-AF4D-AEAC9A47EAA1 Q36403404-682CEFC9-54FC-44A5-9B1F-D4C928C17023 Q36405110-04209A1C-45C8-40C7-B5E8-0A9E1433D372 Q36426782-5B173C33-0003-4F11-A64C-95F13FA3D651

P2860

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

http://www.wikidata.org/entity/Q32085397

description

2001 nî lūn-bûn

@nan

2001 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մարտին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.

@ast

Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.

@en

type

label

Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.

@ast

Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.

@en

prefLabel

Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.

@ast

Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.

@en

P1433

Q32085397-BE28C55A-516A-4B97-B7F0-A4604A577572

P1476

Q32085397-EA43A42B-78BE-491B-B7B0-83D3196F23A0

P2093

Q32085397-1D05AA45-5664-4808-A9DB-4A079826F8C6

Q32085397-29ED0F4E-D97A-44EF-A165-F1E1FEBC89FA

Q32085397-4EB596BD-1508-418D-B00D-141123F2F228

Q32085397-57AB326D-74C8-43C9-97BD-468F79862EC6

Q32085397-58CC4321-CF3F-4B14-B986-D41937A90763

Q32085397-82E92634-B830-4A36-B94A-8B41B3B072FF

Q32085397-8E6C8848-557F-4119-B4FA-25CDB421494D

Q32085397-A0BE22AD-D434-4B84-B244-78C21944D6D4

Q32085397-A48EDBEE-6C31-4531-973E-E91B87868E0E

Q32085397-AC8166AE-6376-44BA-B44B-A58B1E40B018

P304

Q32085397-4FBC7C4D-8E49-4D34-A294-354AC1026B4F

P31

Q32085397-F56BFEB9-6F89-4FE0-BC8C-AF7CD1BCF36E

P356

Q32085397-9C44625B-B5ED-4C1F-9F25-D84EDB99B5C1

P407

Q32085397-6EAE1767-AA3F-4E80-A954-F0B038327886

P433

Q32085397-7E1772C5-A4E4-4EBF-B8A4-905FF2BB78B5

P478

Q32085397-37DB1CE0-6CF5-46C5-8877-ABC83FA9B272

P50

Q32085397-8263AABE-7251-4CEE-B7C9-F306BD737703

P577

Q32085397-B07086D8-1657-4C1D-B7AE-6039B6915591

P698

Q32085397-C5EB7AFB-4584-49FB-B810-3962715F096F

P921

Q32085397-57AA76D4-74F7-4145-9344-A7FA6C7FE03B

Q32085397-78AF963D-F8D5-4B00-A3F9-60B64D1F0C29

P356

01.ATV.21.3.372

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Troglitazone inhibits atherosc ...... cts on CD36 expression and HDL

@en

P2093

F Shionoiri

http://www.w3.org/2001/XMLSchema#string

H Okazaki

http://www.w3.org/2001/XMLSchema#string

H Shimano

http://www.w3.org/2001/XMLSchema#string

K Harada

http://www.w3.org/2001/XMLSchema#string

K Ohashi

http://www.w3.org/2001/XMLSchema#string

N Yamada

http://www.w3.org/2001/XMLSchema#string

Osuga Ji

http://www.w3.org/2001/XMLSchema#string

R Nagai

http://www.w3.org/2001/XMLSchema#string

S Ishibashi

http://www.w3.org/2001/XMLSchema#string

S Perrey

http://www.w3.org/2001/XMLSchema#string

P304

372-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.ATV.21.3.372

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11231916

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis